Anti-IgE: A treatment option in allergic rhinitis?

Allergologie Select Pub Date : 2021-02-24 eCollection Date: 2021-01-01 DOI:10.5414/ALX02205E

Oliver Pfaar, Francesca Gehrt, Hansen Li, Stefan A Rudhart, Alexander Nastev, Boris A Stuck, Stephan Hoch

{"title":"Anti-IgE: A treatment option in allergic rhinitis?","authors":"Oliver Pfaar, Francesca Gehrt, Hansen Li, Stefan A Rudhart, Alexander Nastev, Boris A Stuck, Stephan Hoch","doi":"10.5414/ALX02205E","DOIUrl":null,"url":null,"abstract":"Background: Allergic rhinitis (AR) is the most common IgE-mediated allergic disease. Multiple clinical trials have demonstrated promising results on the AR treatment with biologics, in particular with the use of omalizumab - an anti-IgE antibody. Omalizumab has also been established in the routine management of allergic asthma and chronic idiopathic urticaria. However, currently there is no approved license for the use of biologics in AR in Germany.Materials and methods: A systematic literature review has been completed including randomized controlled trials, meta-analyses, and reviews on the treatment of AR with omalizumab.Results: The systematic review demonstrates strong evidence supporting the use of omalizumab in the treatment of AR with regard to symptom control, safety profile, and management of comorbidities.Conclusion: Omalizumab is a good and safe option in the treatment of AR in terms of symptom control and the management of pre-existing comorbidities. Further clinical trials with other biologics in the management of AR are needed and are expected to follow soon.","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"5 ","pages":"119-127"},"PeriodicalIF":0.0000,"publicationDate":"2021-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905705/pdf/","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologie Select","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5414/ALX02205E","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 6

Abstract

Background: Allergic rhinitis (AR) is the most common IgE-mediated allergic disease. Multiple clinical trials have demonstrated promising results on the AR treatment with biologics, in particular with the use of omalizumab - an anti-IgE antibody. Omalizumab has also been established in the routine management of allergic asthma and chronic idiopathic urticaria. However, currently there is no approved license for the use of biologics in AR in Germany.

Materials and methods: A systematic literature review has been completed including randomized controlled trials, meta-analyses, and reviews on the treatment of AR with omalizumab.

Results: The systematic review demonstrates strong evidence supporting the use of omalizumab in the treatment of AR with regard to symptom control, safety profile, and management of comorbidities.

Conclusion: Omalizumab is a good and safe option in the treatment of AR in terms of symptom control and the management of pre-existing comorbidities. Further clinical trials with other biologics in the management of AR are needed and are expected to follow soon.

Abstract Image

查看原文本刊更多论文

抗ige:过敏性鼻炎的治疗选择?

背景:变应性鼻炎(Allergic rhinitis, AR)是最常见的ige介导的变应性疾病。多项临床试验已经证明了用生物制剂治疗AR的有希望的结果，特别是使用omalizumab——一种抗ige抗体。Omalizumab也被用于过敏性哮喘和慢性特发性荨麻疹的常规治疗。然而，目前在德国还没有批准在AR中使用生物制剂的许可证。材料和方法:已经完成了系统的文献综述，包括随机对照试验、荟萃分析和关于omalizumab治疗AR的综述。结果:系统评价显示了强有力的证据支持在症状控制、安全性和合并症管理方面使用omalizumab治疗AR。结论:在症状控制和预先存在的合并症管理方面，Omalizumab是治疗AR的良好且安全的选择。其他生物制剂在AR治疗中的进一步临床试验是必要的，预计将很快进行。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Allergologie Select

自引率

0.00%

发文量